New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.

ABSTRACT: Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a novel biomedical device approved for use with platinum-pemetrexed, and also for immunotherapy agents to be included as a frontline treatment option in unresectable disease. Although predictive biomarkers for systemic therapy are not currently in use in clinical practice, it is essential to correctly identify the MPM histology to determine an optimal treatment plan. Patients with nonepithelioid MPM may have a greater magnitude of benefit to dual immunotherapy checkpoint inhibitors and this regimen should be preferred in the frontline setting for these patients. However, all patients with MPM can

SUBMITTER: Tsao AS 

PROVIDER: S-EPMC8853621 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature